Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, SEPTEMBER 2, 2021

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.15161?guestAccessKey=b2cebb88-d0dc-43fa-bfee-daeff7dc6594&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090221

 

What The Study Did: Based on a sample of blood donations in the United States from July 2020 through May 2021, vaccine- and infection-induced SARS-CoV-2 seroprevalence increased over time and varied by age, race and ethnicity, and geographic region. Seroprevalence studies estimate how common it is for people to have SARS-CoV-2–specific antibodies due to natural infection or induced by vaccination.

Authors: Jefferson M. Jones, M.D., M.P.H., C.D.R., of the Centers for Disease Control and Prevention in Atlanta, is the corresponding author.

 

(doi:10.1001/jama.2021.15161)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.